The following is a summary of “Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis,” published in the November 2023 issue of Opthalmology by Karpecki et al.
Dry eye disease (DED) is a common condition that causes inflammation and damage to the ocular surface. The incidence of DED increases with age. OTX-101, Restasis, and Xiidra are anti-inflammatory medications that are used to treat DED.
In a retrospective study, researchers compared treatment patterns in DED patients receiving OTX-101, CsA, or LFT.
They utilized Symphony Health Integrated Dataverse claims. The dataset comprised all patients with OTX-101 claims and randomly chosen patients with CsA or LFT claims at a 2:1 ratio compared to OTX-101. Patients were sorted into three groups based on the first treatment and followed until activity ended or data became unavailable. Time to treatment discontinuation (TTD), discontinuation probability, and treatment persistence were assessed for OTX-101 compared to CsA and subsequently versus LFT. Age and prior DED treatment were used to analyze subgroup TTD and index treatment discontinuation. The results encompassed unadjusted and adjusted odds ratios, 95% CIs, and P-values, indicating statistical significance below P < 0.05.
The results showed 7,102 patients (OTX-101 n = 1,846; CsA n = 2248; LFT n = 3,008) eligible for the study. Patients on OTX-101 had a median TTD of 354 days compared to 241 days for CsA and 269 days for LFT. The log-rank test revealed that the TTD was significantly longer for those on OTX-101 than CsA (P=0.033). Patients using CsA were 35% more likely to discontinue treatment than those on OTX-101, while discontinuation rates for OTX-101 and LFT groups were similar. At the 360-day mark, 49.8% of OTX-101 patients remained on treatment compared to 39.4% of CsA patients (P=0.036) and 44.0% of LFT patients (P=0.854).
They concluded that OTX-101 treatment was associated with longer persistence and lower discontinuation rates than CsA, especially in older adults.
Source: bmcophthalmol.biomedcentral.com/articles/10.1186/s12886-023-03174-y
